Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting

Paul Spearman, Emory University
G. Tomaras, Duke Human Vaccine Institute
D. Montefiori, Duke Human Vaccine Institute
Y. Huang, Fred Hutchinson Cancer Research Center
H. Ahmed, Fred Hutchinson Cancer Research Center
M. Elizaga, Fred Hutchinson Cancer Research Center
J. Hural, Fred Hutchinson Cancer Research Center
J. McElrath, Fred Hutchinson Cancer Research Center
L. Ouedraogo, NIAID
M. Pensiero, NIAID

Only first 10 authors above; see publication for full author list.

Journal Title: Retrovirology
Volume: Volume 9, Number Suppl 2
Publisher: BioMed Central | 2012-09-13, Pages P137-P137
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/1742-4690-9-S2-P137
Permanent URL: https://pid.emory.edu/ark:/25593/s5f2r

Final published version: http://dx.doi.org/10.1186/1742-4690-9-S2-P137

Copyright information:
©2012 Spearman et al
This is an Open Access work distributed under the terms of the Creative Commons Attribution 2.0 Generic License (http://creativecommons.org/licenses/by/2.0/).

Accessed November 29, 2019 4:46 PM EST
Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting

P Spearman1*, G Tomaras2, D Montefiori2, Y Huang3, H Ahmed3, M Elizaga3, J Hural3, J McElrath3, L Ouedraogo4, M Pensiero4, C Butler4, S Kalams5, ET Overton6, S Barnett7, N Group1

From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012

Background
Immunization with heterologous Env protein immunogens following an immunologic rest period has the potential to generate cross-clade neutralizing antibody responses. We identified individuals who had received a clade B Env protein with MF59 4-17 years earlier, most in combination with a DNA or ALVAC prime, and administered a clade C protein boost in an open label phase 1 trial.

Methods
Sixteen previously primed volunteers and 20 naïve volunteers each received 2 doses of a clade C TV1 trimeric Env protein with MF59 given 6 months apart. HIV-1 specific CD4+ and CD8+ T cell responses were measured by an intracellular cytokine staining (ICS) assay. Antibody responses were measured with a Luminex binding antibody assay and a neutralizing antibody assay in TZM-bl Cells.

Results
Despite the long interval, 31% of primed participants demonstrated CD4+ T cell responses to Env at baseline, which increased to 75% after a single protein boost. IgG and IgA responses to TV1 trimeric Env were present in 64% (IgG) and 7% (IgA) of primed participants at baseline, and rose to 93% and 85%, respectively, after one dose of protein. 71% of primed participants demonstrated neutralizing antibodies against Tier 1 clade B isolate MN at baseline. After a single booster dose of protein, 100% of the primed participants neutralized MN and 93% showed neutralizing activity against a clade C isolate, MW965.26. Unprimed participants did not demonstrate CD4+ responses or antibody responses to Env until after the second dose, which elicited IgG and IgA responses to TV1 trimeric Env in 88% and 50%, respectively. Neutralizing antibody developed to MN in 38% and to MW965.26 in 88% of the unprimed participants.

Conclusion
These results demonstrate the durability of vaccine-elicited HIV-1 specific antibody responses and support current efforts to enhance the breadth and magnitude of neutralizing antibodies through heterologous protein prime-boost regimens.

Author details
1Emory University, Atlanta, GA, USA. 2Department of Surgery, Duke Human Vaccine Institute, Durham, NC, USA. 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4Division of AIDS, NIAID, NIH, Bethesda, MD, USA. 5Vanderbilt University School of Medicine, Nashville, TN, USA. 6University of Alabama at Birmingham, Birmingham, AL, USA. 7Novartis Vaccines and Diagnostics, Cambridge, MA, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P137

Cite this article as: Spearman et al: Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting. Retrovirology 2012 9(Suppl 2):P137.